Treatment of diabetic macular edema using aflibercept in vitrectomized eyes following five bevacizumab injections failure

Poster Details

First Author: P.Yilmazbas TURKEY

Co Author(s):    S. Doguizi   M. Sekeroglu                          

Abstract Details


To present a case with bilateral diabetic macular edema in post-vitrectomized eyes successfully treated with aflibercept injection following poor response to initial bevacizumab injections.


Ulucanlar Eye Training and Research Hospital, Ankara, Turkey


We present a case of an 54-year-old female, who had undergone bilateral vitrectomy surgery for proliferative diabetic retinopathy three years ago. The bilaterally diabetic macular edema started to be appeared after two years from vitrectomy surgery.


The patient was examined at two years after surgery and revealed bilateral cystoid macular edema. On exam, her visual acuity was 20/320 in the left and 20/400 in right eye. Optical coherence tomography (OCT) imaging demonstrated bilateral cystoid macular edema. The patient was treated with five following intravitreal injections of bevacizumab 1.25 mg bilaterally, but diabetic macular edema was not improved. Given the absence of appropriate response, the decision was made to switch treatment to aflibercept 2.0 mg bilaterally. One month after a single aflibercept injection, her visual acuity dramatically improved to 20/200 in left eye, 20/250 in right eye and OCT imaging demonstrated a significant decrease in macular edema. The patient’s visual acuity remained stable bilaterally during four months following a single dose of aflibercept injection.


Vitrectomized eyes may require increased frequency of anti-VEGF therapy due to possible changes in drug availability and using an agent with a higher binding affinity, like aflibercept, may provide clinical stability.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy